Carolyn Liebsack

Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort

David L. Sparks, Richard J. Kryscio, Marwan Sabbagh et al. · Current Alzheimer Research · 2008 · 123 citations

Medicine, Neurology, Pharmacotherapy +16

Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia

Marwan N. Sabbagh, Kewei Chen, Joseph Rogers et al. · Alzheimer s & Dementia · 2015 · 70 citations

Medicine, Neurology, Nuclear Medicine +17

Cholesterol and Cognitive Performance in Normal Controls and the Influence of Elective Statin Use after Conversion to Mild Cognitive Impairment: Results in a Clinical Trial Cohort

David L. Sparks, Richard J. Kryscio, Donald J. Connor et al. · Neurodegenerative Diseases · 2010 · 49 citations · Full text

Medicine, Geriatric Medicine, Neurology +17

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders

Andrew Siderowf, Michael J. Pontecorvo, Holly A. Shill et al. · BMC Neurology · 2014 · 46 citations · Full text

Medicine, Neurology, Neuroscience +17

Tau is reduced in AD plasma and validation of employed ELISA methods.

David L. Sparks, Richard J. Kryscio, Marwan N. Sabbagh et al. · PubMed · 2012 · 43 citations · Full text

Medicine, Neurology, Neuroscience +17